Role of the prostaglandin pathway and the use of NSAIDs in genitourinary malignancies

Expert Review of Anticancer Therapy

Volumn 8, Issue 7, 2008, Pages 1125-1134

  Taylor III, John A ^a   Pilbeam, Carol ^a   Nisbet, Andrew ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Bladder; Cancer; COX; Nonsteroidal; Prostaglandins; Prostate; Renal

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CALCITRIOL; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; EPIGALLOCATECHIN GALLATE; ETODOLAC; GENISTEIN; IBUPROFEN; INDOMETACIN; INTERFERON; LICOFELONE; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SALICYLIC ACID; SULINDAC; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; APOPTOSIS; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CANCER RADIOTHERAPY; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE MODEL; DISEASE SEVERITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG USE; HUMAN; HYPERTHERMIC THERAPY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MONOTHERAPY; NONHUMAN; PROSTATE CANCER; REVIEW; UROGENITAL TRACT CANCER; UROTHELIUM; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; UROGENITAL TRACT TUMOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ARACHIDONIC ACID; CYCLOOXYGENASE INHIBITORS; HUMANS; PROSTAGLANDINS; SIGNAL TRANSDUCTION; UROGENITAL NEOPLASMS;

EID: 48849110790     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.7.1125     Document Type: Review

References (124)

1. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J. Lipid Res. 41(2), 163-181 (2000).
2. Murphy RC, Bowers RC, Dickinson JD, Berry KZ. Perspectives on the biosynthesis and metabolism of eicosanoids. In: The Eicosanoids. Curtis-Prior P (Ed.). John Wiley & Sons, Ltd, West Sussex, England 3-16 (2004).
3. Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochem. J. 259(2), 315-324 (1989).
4. Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J. Cell Mol Med. 7(3), 207-222 (2003).
5. Eschwege P, Ferlicot S, Droupy S et al. A histopathologic investigation of PGE(2) pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder. Eur. Urol. 44(4), 435-441 (2003).
6. Smith WL, Song I. The enzymology of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat. 68-69, 115-128 (2002).
7. Kulmacz RJ, van der Donk WA, Tsai AL. Comparison of the properties of prostaglandin H synthase-1 and -2. Prog. Lipid Res. 42(5), 377-404 (2003).
8. Rouzer CA, Marnett LJ. Structural and functional differences between cyclooxygenases: fatty acid oxygenases with a critical role in cell signaling. Biochem. Biophys. Res. Commun. 338(1), 34-44 (2005).
9. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145-182 (2000).
10. Simmons DI, Betting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56(3), 387-437 (2004).
11. Smith WL, Langenbach R. Why there are two cyclooxygcnase isozymes. J. Clin. Invest. 107(12), 1491-1495 (2001).
12. Kang YJ, Mbonye UR, DeLong CJ, Wada M, Smith WL. Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog. Lipid Res. 46(2), 108-125 (2007).
13. Xu Z, Choudhary S, Okada Y et al. Cyclooxygenase-2 gene disruption promotes proliferation of murine calvarial osteoblasts in vitro. Bone 41(1), 68-76 (2007).
14. Choudhary S, Wadhwa S, Raisz LG, Alander C, Pilbeam CC. Extracellular calcium is a potent inducer of cyclo-oxygenase-2 in murine osteoblasts through an ERK signaling pathway. J. Bone Miner. Res. 18(10), 1813-1824 (2003).
15. Chikazu D, Li X, Kawaguchi H et al. Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. J. Bone Miner. Res. 17(8), 1430-1440 (2002).
16. Kang S, Kim YB, Kim MH et al. Polymorphism in the nuclear factor κ-B binding promoter region of cydooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett. 217(1), 11-16 (2005).
17. Masferrer JL, Leahy KM, Koki AT et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60(5), 1306-1311 (2000).
18. Chang SH, Liu CH, Conway R et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc. Natl Acad. Sci. USA 101(2), 591-596 (2004).
19. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu. Rev. Med. 58, 239-252 (2007).
20. Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ. Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc. Soc. Exp. Biol. Med. 216(2), 201-210 (1997).
21. Yoshimura R, Sano H, Mitsuhashi M et al. Expression of cyclooxygenase-2 in patients with bladder carcinoma. J. Urol. 165(5), 1468-1472 (2001).
22. Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J. Clin. Invest. 100(6), 1325-1329 (1997).
23. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57(7), 1276-1280 (1997).
24. Sano H, Kawahito Y, Wilder RL et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer. Res. 55(17), 3785-3789 (1995).
25. Tucker ON, Dannenberg AJ, Yang EK et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59(5), 987-990 (1999).
26. Kirschenbaum A, Klausner AP, Lee R et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 56(4), 671-676 (2000).
27. Wang D, Dubois RN. Prostaglandins and cancer. Gut 55(1), 115-122 (2006).
28. Pruthi RS, Wallen EM. Cyclooxygenase-2: a therapeutic target for prostate cancer. Clin. Genitourin. Cancer 4(3), 203-211 (2005).
29. Pereg D, Lishner M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J. Intern. Med. 258(2), 115-123 (2005).
30. Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342(26), 1946-1952 (2000).
31. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352(11), 1092-1102 (2005).
32. Mohammed SI, Dhawan D, Abraham S et al. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects 10.1158/1535-7163.MCT-05-0117. Mol. Cancer Ther. 5(2), 329-336 (2006).
33. Bostrom PJ, Uotila P, Rajala P et al. Interferon-α inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro. Urol. Res. 29(1), 20-24 (2001).
34. Yu DS, Chen HI, Chang SY. The expression of cyclooxygenase in transitional cell carcinoma cell lines: its correlation with tumor differentiation, invasiveness and prostanoids production. Eur. Urol. 44(4), 491-494 (2003).
35. Gee J, Lee IL, Jendiroba D et al. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol. Rep. 15(2), 471-477 (2006).
36. Mohseni H, Zaslau S, McFadden D et al. COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro. J. Surg. Res. 119(2), 138-142 (2004).
37. Kitayama W, Denda A, Okajima E, Tsujiuchi T, Konishi Y. Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Carcinogenesis 20(12), 2305-2310 (1999).
38. Shi Y, Cui L, Dai G et al. Elevated prostaglandin E2 level via cPLA2-COX-2-mPGES-1 pathway involved in bladder carcinogenesis induced by terephthalic acid-calculi in Wistar rats. Prostaglandins Leukot. Essent. Fatty Acids 74(5), 309-315 (2006).
39. Knottenbelt C, Mellor D, Nixon C, Thompson H, Argyle DJ. Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumours. J. Small Anim. Pract. 47(4), 196-200 (2006).
40. Landolfi JA, Terio KA. Transitional cell carcinoma in fishing cats ( Prionailurus viverrinus): pathology and expression of cyclooxygenase-1, -2, and p53. Vet. Pathol. 43(5), 674-681 (2006).
41. Klein RD, Van Pelt CS, Sabichi AL et al. Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res. 65(5), 1808-1813 (2005).
42. Grubbs CJ, Juliana MM, Eto I et al. Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors. Anticancer Res. 13(1), 33-36 (1993).
43. Grubbs CJ, Luber RA, Koki AT et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6d2F1 mice and female Fischer-344 rats. Cancer Res. 60(20), 5599-5602 (2000).
44. Okajima E, Denda A, Ozono S et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res. 58(14), 3028-3031 (1998).
45. Mohammed SI, Knapp DW, Bostwick DG et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. 59(22), 5647-5650 (1999).
46. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin. Cancer Res. 6(6), 2424-2430 (2000).
47. Ristimaki A, Nieminen O, Saukkonen K et al. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am. J. Pathol. 158(3), 849-853 (2001).
48. Shariat SF, Kim JH, Ayala GE et al. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J. Urol. 169(3), 938-942 (2003).
49. Margulis V, Shariat SF, Ashfaq R et al. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J. Urol. 177(3), 1163-1168 (2007).
50. Shirahama T, Arima J, Akiba S, Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 92(1), 188-193 (2001).
51. Shariat SF, Matsumoto K, Kim J et al. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J. Urol. 170(3), 985-989 (2003).
52. Wadhwa P, Goswami AK, Joshi K, Sharma SK. Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. Int. Urol. Nephrol. 37(1), 47-53 (2005).
53. Pruthi RS, Derksen E, Gaston K, Wallen EM. Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer. Urology 64(4), 637-642 (2004).
54. Sheehy O, Zhao S, Raymoundo A et al. Celecoxib associated with reduced risk of superficial bladder cancer (SBC) recurrence. Proc. Am. Soc. Clin. Oncol. 22, 1539 (2003).
55. Fortuny J, Kogevinas M, Garcia-Closas M et al. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol. Biomarkers Prev. 15(9), 1696-1702 (2006).
56. Genkinger JM, De Vivo I, Stampfer MJ, Giovannucci E, Michaud DS. Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow-up study. Int. J. Cancer 120(10), 2221-2225 (2007).
57. Zha S, Gage WR, Sauvageot J et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate but not in prostate carcinoma. Cancer Res. 61(24), 8617-8623 (2001).
58. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-α in normal and malignant prostate cells. Cancer Res. 61(6), 2720-2726 (2001).
59. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bc1-2 expression in LNCaP cells. Cancer Res. 58(19), 4245-4249 (1998).
60. Shigemura K, Shirakawa T, Wada Y et al. Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo. Urology 66(6), 1239-1244 (2005).
61. Kamijo T, Sato T, Nagatomi Y, Kitamura T. Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int. J. Urol. 8(7), S35-S39 (2001).
62. Narayanan NK, Nargi D, Artur M, Abramson SB, Narayanan BA. Anticancer effects of licofelone (ML-3000) in prostate cancer cells. Anticancer Res. 27(4B), 2393-2402 (2007).
63. Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic: adenocarcinoma mouse prostate model. Clin. Cancer Res. 10(22), 7727-7737 (2004).
64. Narayanan BA, Reddy BS, Bosland MC et al. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence. Clin. Cancer Res. 13(19), 5965-5973 (2007).
65. Gupta S, Adhami VM, Subbarayan M et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 64(9), 3334-3343 (2004).
66. Nithipatikom K, Isbell MA, Lindholm PF et al. Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin. Exp. Metastasis 19(7), 593-601 (2002).
67. Fujita H, Koshida K, Keller ET et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53(3), 232-240 (2002).
68. Liu XH, Kirschenbaum A, Yao S et al. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin. Exp. Metastasis 17(8), 687-694 (1999).
69. Dandekar DS, Lokeshwar BL. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin. Cancer Res. 10(23), 8037-8047 (2004).
70. Liu XH, Kirschenbaum A, Yao S et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J. Urol. 164(3 Pt 1), 820-825 (2000).
71. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int. J. Cancer 115(3), 484-492 (2005).
72. Mehar A, Macanas-Pirard P, Mizokami A et al. The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents. J. Pharmacol. Exp. Ther. 324(3), 1181-1187 (2008).
73. Wang Y, Colby JK, Yang P et al. The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue. Carcinogenesis 29(1), 120-128 (2008).
74. Anai S, Tanaka M, Shiverick KT et al. Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells. J. Urol. 177(5), 1913-1917 (2007).
75. Asea A, Mallick R, Lechpammer S et al. Cyclooxygenase inhibitors are potent sensitizers of prostate tumours to hyperthermia and radiation. Int. J. Hyperthermia 17(5), 401-414 (2001).
76. Yoshimura R, Sano H, Masuda C et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89(3), 589-596 (2000).
77. Lee LM, Pan CC, Cheng CJ, Chi CW. Liu TY. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res. 21(2B), 1291-1294 (2001).
78. Cohen BL, Gomez P. Omori Y et al. Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int. J. Cancer 119(5), 1082-1087 (2006).
79. Khor LY, Bae K, Pollack A et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol. 8(10), 912-920 (2007).
80. Cheng I, Liu X, Plummer SJ et al. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br. J. Cancer 97(4), 557-561 (2007).
81. Shahedi K, Lindstrom S, Zheng SL et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int. J. Cancer 119 (3), 668-672 (2006).
82. Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results ofcase control studies. Subcell Biochem. 42, 193-212 (2007).
83. Jacobs EJ, Rodriguez C, Mondul AM et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J. Natl Cancer Inst. 97(13), 975-980 (2005).
84. Platz EA, Robrmann S, Pearson JD et al. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol. Biomarkers Prev. 14(2), 390-396 (2005).
85. Pruthi RS, Derksen JE, Moore D et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin. Cancer Res. 12(7 Pt 1), 2172-2177 (2006).
86. Smith MR, Manola J, Kaufman DS et al. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J. Clin. Oncol. 24(18), 2723-2728 (2006).
87. Beer TM, Lemmon D, Lowe BA, Henner WD. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 97(5), 1217-1224 (2003).
88. Chen Q, Shinohara N, Abe T et al. Significance of COX-2 expression in human renal cell carcinoma cell lines. Int. J. Cancer 108(6), 825-832 (2004).
89. Chen Q, Shinohara N, Abe T, Harabayashi T, Nonomura K. Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line. J. Urol. 172(6 Pt 1), 2153-2157 (2004).
90. Ou YC, Yang CR, Cheng CL et al. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. Eur. J. Pharmacol. 563(1-3), 49-60 (2007).
91. Miyata Y, Koga S, Kanda S et al. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin. Cancer Res. 9(5), 1741-1749 (2003).
92. Yoshimura R, Matsuyama M, Kawahito Y et al. Study of cyclooxygenase-2 in renal cell carcinoma. Int. J. Mol. Med. 13(2), 229-233 (2004).
93. Hashimoto Y, Kondo Y, Kimura G et al. Cyclooxygenase-2 expression and relationship to turmour progression in human renal cell carcinoma. Histopathology 44(4), 353-359 (2004).
94. Rini BI, Weinberg V, Dunlap S et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 106(3), 566-575 (2006).
95. Xu Z, Choudhary S, Voznesensky O et al. Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis. Cancer Res. 66(13), 6657-6664 (2006).
96. Kashfi K, Rigas B. Is COX-2 a 'collateral' target in cancer prevention? Biochem. Soc. Trans. 33(Pt 4), 724-727 (2005).
97. Patel MI, Subbarasmiah K, Du B et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin. Cancer Res. 11(5), 1999-2007 (2005).
98. Naruse T, Nishida Y, Hosono K, Ishiguso N. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 27(3), 584-592 (2006).
99. Fries S, Grosser T, Price TS et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology, 130(1), 55-64 (2006).
100. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. Faseb. J. 22(2), 383-390 (2008).
101. Hinz B, Brune K. Antipyretic analgesics: nonsteroidal antiinflammatory drugs, selective COX-2 inhibitors, paracetamol and pyrazolinones. Handb. Exp. Pharmacol. (177), 65-93 (2007).
102. Mehrotra S, Morimiya A, Agarwal B, Konger R, Badve S. Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J. Pathol. 208(3), 356-363 (2006).
103. Backlund MG, Mann JR, Holla VR et al. 15-hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem. 280(5), 3217-3223 (2005).
104. Mann JR, Backlund MG, Buchanan FG et al. Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res. 66(13), 6649-6656 (2006).
105. Ding Y, Tong M, Liu S, Moscow JA, Tai HH. NAD+-finked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 26(1), 65-72 (2005).
106. Gee JR, Montoya RG, Khaled HM, Sabichi AL, Grossman HB. Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol. Oncol. 21(4), 266-270 (2003).
107. Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res. 66(20), 9794-9797 (2006).
108. Watanabe K, Kawamori T, Nakatsugi S et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 59(20), 5093-5096 (1999).
109. Mutoh M, Watanabe K, Kitamura T et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 62(1), 28-32 (2002).
110. Amano H, Hayashi I, Endo H et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associatcd angiogenesis and tumor growth. J. Exp. Med. 197(2), 221-232 (2003).
111. Makita H, Mutoh M, Maruyama T et al. A prostaglandin E2 receptor subtype EPI-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Carcinogenesis 28(3), 677-684 (2007).
112. Wang X, Klein RD. Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway. Mol. Carcinog. 46(11), 912-923 (2007).
113. Miyata Y, Kanda S, Maruta S et al. Relationship between prostaglandin E2 receptors and clinicopathologic features in human prostate cancer tissue. Urology 68(6), 1360-1365 (2006).
114. Miyata Y, Ohba K, Kanda S et al. Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract. Virchows Arch. 448(6), 822-829 (2006).
115. Miyata Y, Kanda S, Nomata K, Eguchi J, Kanetake H. Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract. J. Urol. 173(1), 56-60 (2005).
116. Krishnan AV, Moreno J, Norin L et al. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J. Steroid. Biochem. Mol. Biol. 103(3-5), 694-702 (2007).
117. Krishnan AV, Moreno J, Nonn L et al. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J. Bone Miner. Res. 22(Suppl. 2), V74-V80 (2007).
118. Moreno J, Krishnan AV, Peehl DM, Feldman D. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res. 26(4A), 2525-2530 (2006).
119. Krishnan AV, Swami S, Moreno J et al. Potentiation of the growth-inhibitory effects of vitamin D in prostate cancer by genistein. Nutr. Rev. 65(8 Pt 2), S121-S123 (2007).
120. Swami S, Krishnan AV, Moreno J et al. Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J. Nutr. 137(1 Suppl.), 205S-210S (2007).
121. Hussain T, Gupta S, Adhami VM, Mukhtar H. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int. J. Cancer 113(4), 660-669 (2005).
122. Gupta S, Hussain T, Mukhtar H. Molecular pathway for (-)epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch. Biochem. Biophys. 410(1), 177-185 (2003).
123. Adhami VM, Malik A, Zaman N et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 13(5), 1611-1619 (2007).
124. Siddiqui IA, Adhami VM, Saleem M, Mukhtar H. Beneficial effects of tea and its polyphenols against prostate cancer. Mol. Nutr. Food Res. 50(2), 130-143 (2006).